HK1042244A1 - 包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物 - Google Patents

包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物 Download PDF

Info

Publication number
HK1042244A1
HK1042244A1 HK02104004.4A HK02104004A HK1042244A1 HK 1042244 A1 HK1042244 A1 HK 1042244A1 HK 02104004 A HK02104004 A HK 02104004A HK 1042244 A1 HK1042244 A1 HK 1042244A1
Authority
HK
Hong Kong
Prior art keywords
nsaid
colorectal cancer
kinase inhibitor
inhibition
treatment
Prior art date
Application number
HK02104004.4A
Other languages
English (en)
Chinese (zh)
Inventor
Frost Philip
Mary Discafani-Marro Carolyn
Original Assignee
Wyeth Holdings Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings Corporation filed Critical Wyeth Holdings Corporation
Publication of HK1042244A1 publication Critical patent/HK1042244A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK02104004.4A 1999-08-12 2000-08-02 包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物 HK1042244A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37326199A 1999-08-12 1999-08-12
US09/373,261 1999-08-12
PCT/US2000/021021 WO2001012227A1 (en) 1999-08-12 2000-08-02 Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer

Publications (1)

Publication Number Publication Date
HK1042244A1 true HK1042244A1 (zh) 2002-08-09

Family

ID=23471660

Family Applications (1)

Application Number Title Priority Date Filing Date
HK02104004.4A HK1042244A1 (zh) 1999-08-12 2000-08-02 包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物

Country Status (24)

Country Link
EP (1) EP1202746B1 (https=)
JP (1) JP2003507342A (https=)
KR (1) KR20020018201A (https=)
CN (1) CN1229142C (https=)
AR (1) AR029763A1 (https=)
AT (1) ATE341341T1 (https=)
AU (1) AU783116B2 (https=)
BR (1) BR0013219A (https=)
CA (1) CA2380904C (https=)
CZ (1) CZ2002474A3 (https=)
DE (1) DE60031127T2 (https=)
DK (1) DK1202746T3 (https=)
EA (1) EA006876B1 (https=)
ES (1) ES2272305T3 (https=)
HK (1) HK1042244A1 (https=)
HU (1) HUP0203162A3 (https=)
IL (1) IL147913A0 (https=)
MX (1) MXPA02001448A (https=)
NO (1) NO20020663L (https=)
NZ (1) NZ517120A (https=)
PL (1) PL353267A1 (https=)
PT (1) PT1202746E (https=)
WO (1) WO2001012227A1 (https=)
ZA (1) ZA200201156B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040127470A1 (en) * 1998-12-23 2004-07-01 Pharmacia Corporation Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
US6384051B1 (en) 2000-03-13 2002-05-07 American Cyanamid Company Method of treating or inhibiting colonic polyps
CN1190197C (zh) * 2000-03-13 2005-02-23 惠氏控股公司 氰基喹啉用于制备治疗或抑制结肠息肉药物中的用途
EP1412367A4 (en) 2001-06-21 2006-05-03 Ariad Pharma Inc NEW CHINOLINE AND ITS USE
WO2003008409A1 (en) 2001-07-16 2003-01-30 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
US20050043409A1 (en) * 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
DE60313339T2 (de) 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
US7629347B2 (en) 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
WO2004046386A1 (en) * 2002-11-15 2004-06-03 Genomic Health, Inc. Gene expression profiling of egfr positive cancer
AU2004253967B2 (en) 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
KR20080095915A (ko) 2004-05-06 2008-10-29 워너-램버트 캄파니 엘엘씨 4-페닐아미노-퀴나졸린-6-일-아미드
RU2006146612A (ru) 2004-06-03 2008-07-20 Ф.Хоффманн-Ля Рош Аг (Ch) Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr)
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP5191391B2 (ja) 2005-11-01 2013-05-08 ターゲジェン インコーポレーティッド キナーゼのビ−アリールメタ−ピリミジン阻害剤
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
AU2008212999A1 (en) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
US8497369B2 (en) 2008-02-07 2013-07-30 Boehringer Ingelheim International Gmbh Spirocyclic heterocycles medicaments containing said compounds, use thereof and method for their production
JP5739802B2 (ja) 2008-05-13 2015-06-24 アストラゼネカ アクチボラグ ４−（３−クロロ−２−フルオロアニリノ）−７−メトキシ−６−｛［１−（ｎ−メチルカルバモイルメチル）ピペリジン−４−イル］オキシ｝キナゾリンのフマル酸塩
ES2396613T3 (es) 2008-05-19 2013-02-22 OSI Pharmaceuticals, LLC Imidazopirazinas e imidazotriazinas sustituidas
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
PL387312A1 (pl) 2009-02-19 2010-08-30 Farma-Projekt Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie sulindaku i/lub jego metabolitu we wspomagającym leczeniu raka jelita grubego u ludzi
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
US8513415B2 (en) 2009-04-20 2013-08-20 OSI Pharmaceuticals, LLC Preparation of C-pyrazine-methylamines
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy
CA2837227C (en) * 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL135900A0 (en) * 1997-11-04 2001-05-20 Pfizer Prod Inc Indazole bioisostere replacement of catechol in therapeuticaly active compounds
BR9814116A (pt) * 1997-11-06 2000-10-03 American Cyanamid Co Uso de derivados de quinazolina como inibidores de cinase de tirosina para tratamento de pólipo colÈnico

Also Published As

Publication number Publication date
DE60031127T2 (de) 2007-02-01
EP1202746A1 (en) 2002-05-08
DE60031127D1 (de) 2006-11-16
HUP0203162A3 (en) 2006-07-28
EA200200246A1 (ru) 2002-08-29
MXPA02001448A (es) 2002-07-02
AR029763A1 (es) 2003-07-16
HUP0203162A2 (hu) 2003-01-28
AU783116B2 (en) 2005-09-29
CA2380904A1 (en) 2001-02-22
BR0013219A (pt) 2002-04-23
KR20020018201A (ko) 2002-03-07
EP1202746B1 (en) 2006-10-04
NO20020663D0 (no) 2002-02-11
ZA200201156B (en) 2003-05-12
CA2380904C (en) 2009-02-10
DK1202746T3 (da) 2007-01-02
JP2003507342A (ja) 2003-02-25
EA006876B1 (ru) 2006-04-28
PL353267A1 (en) 2003-11-03
CN1370080A (zh) 2002-09-18
IL147913A0 (en) 2002-08-14
PT1202746E (pt) 2007-01-31
ATE341341T1 (de) 2006-10-15
ES2272305T3 (es) 2007-05-01
WO2001012227A1 (en) 2001-02-22
AU6395900A (en) 2001-03-13
NO20020663L (no) 2002-04-09
NZ517120A (en) 2004-10-29
CZ2002474A3 (cs) 2003-02-12
CN1229142C (zh) 2005-11-30

Similar Documents

Publication Publication Date Title
HK1042244A1 (zh) 包含可治疗或抑制结肠息肉及结肠直肠癌的成份的nsaid与efgr激酶抑制物
IL151249A0 (en) Use of cyanoquinolines for treating or inhibiting colonic polyps
DK1286671T3 (da) Sammensætninger til behandling af colorektal cancer hvilke indeholder thalidomid og irinotecan
WO2005018677A3 (en) Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
WO2001005392A3 (en) Method for treating chronic pain using mek inhibitors
PL340800A1 (en) Application of quinazoline derivatives as inhibitors of thyrosinic kinase in treating colonic polyps
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
NO20024610D0 (no) Synergistiske metoder og blandinger for behandling av kreft
WO2004105700A3 (en) Compounds, methods and pharmaceutical compositions for inhibiting parp
WO1994004541A3 (en) Protein kinase inhibitors and related compounds combined with taxol
WO2002039994A3 (en) Methods for the treatment and prevention of urinary stone disease
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
AU2001266838A1 (en) Inhibitors of matriptase for the treatment of cancer
WO2003090753A8 (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention
PL368271A1 (en) Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine
AU2002311859A1 (en) Compositions and methods for treating colorectal polyps and cancer
AU2001232060A1 (en) Use of cyp1b1 inhibitors for treating cancer
AU3919001A (en) Use of 2-methyl-thiazolidin-2,4-dicarboxylic acid (2-mtdc) and/or physiologically compatible salts for treating and/or preventing cancers
AU2001278738A1 (en) Medicinal compositions for preventing and treating cancer
WO2002032429A3 (en) Use of inhibitors of progesterone receptor for treating cancer
AU2002337713A1 (en) Pharmaceutical compositions and methods for treating cancer
EE200300057A (et) Koostis vähi profülaktikaks ja raviks
SI1202746T1 (sl) FARMACEVTSKA OBLIKA, KI VSEBUJE NSAID in ZAVIRALEC KINAZE EGFR, ZA ZDRAVLJENJE ALI PREPRECEVANJE POLIPOV DEBELEGA CREVESA IN KOLOREKTALNEGA RAKA
EP1300159A4 (en) REMEDIES FOR CANCER